Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Uniqure NV (QURE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Uniqure NV's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.560 -0.190    -4.00%
21:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
4.700
+0.140
+3.070%
22:47:55 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 565,569
  • Bid/Ask: 4.400 / 4.680
  • Day's Range: 4.480 - 4.780
Uniqure NV 4.560 -0.190 -4.00%

Uniqure NV Company Profile

 
Get an in-depth profile of Uniqure NV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

480

Equity Type

ORD

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Contact Information

Address Paasheuvelweg 25
Amsterdam, 1105 BP
Netherlands
Phone 31 20 240 6000
Fax -

Top Executives

Name Age Since Title
Jesús Prieto - - Member of Scientific Advisory Board
Robin Ali - - Member of Scientific Advisory Board
Michael R. Hayden 72 - Member of Scientific Advisory Board
Robert Gut 58 2018 Non-Executive Director
David D. Meek 60 2018 Independent Chairman of the Board
Paula Soteropoulos 55 2013 Independent Non-Executive Director
Madhavan Balachandran 72 2017 Independent Non-Executive Director
Matthew Craig Kapusta 51 2015 CEO & Executive Director
Leonard E. Post 70 2020 Independent Non-Executive Director
Jeremy P. Springhorn 61 2017 Independent Non-Executive Director
Jack L. Kaye 79 2016 Independent Non-Executive Director
Rachelle Suzanne Jacques 52 2021 Non-Executive Director
Hugo Katus - 2014 Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

QURE Comments

Write your thoughts about Uniqure NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email